A5101429357- Monoclonal and Polyclonal Antibodies Research
- Cancer Mechanisms and Therapy
- Melanoma and MAPK Pathways
- Chronic Lymphocytic Leukemia Research
- Ubiquitin and proteasome pathways
- Synthesis and Biological Evaluation
- Cancer therapeutics and mechanisms
- Click Chemistry and Applications
- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer survivorship and care
- Synthesis and Biological Activity
- Synthetic Organic Chemistry Methods
- Advanced Breast Cancer Therapies
- Chemical Reactions and Isotopes
- Vector-Borne Animal Diseases
- Biosimilars and Bioanalytical Methods
- Signaling Pathways in Disease
- Histone Deacetylase Inhibitors Research
- Pancreatic and Hepatic Oncology Research
- Biochemical and Molecular Research
- Immune Cell Function and Interaction
- Cancer-related Molecular Pathways
- Protein Degradation and Inhibitors
PharmaMar (Spain)
2006-2013
Universidad Autónoma de Madrid
2007
Instituto de Investigaciones Biomédicas Sols-Morreale
2007
Consejo Superior de Investigaciones Científicas
2007
Eli Lilly (United States)
1999-2002
Institute of Astronomy and Space Physics
1997
Melanoma is the most aggressive skin cancer and a serious health problem worldwide because of its increasing incidence lack satisfactory chemotherapy for late stages disease. The marine depsipeptide Aplidin (plitidepsin) an antitumoral agent under phase II clinical development against several neoplasias, including melanoma. We report that plitidepsin has dual effect on human SK-MEL-28 UACC-257 melanoma cell lines; at low concentrations (≤45 nM), it inhibits cycle by inducing G<sub>1</sub>...
Aplidin® is an antitumour drug, currently undergoing phase II evaluation in different haematological and solid tumours. In this study, we analysed the antimyeloma effects of Aplidin syngeneic 5T33MM model, which representable for human disease. vitro, inhibited 5T33MMvv DNA synthesis with IC50 3.87 nM. On cell-cycle progression, drug induced arrest transition from G0/G1 to S phase, while Western blot showed a decreased cyclin D1 CDK4 expression. Furthermore, apoptosis by lowering...
Aplidin (plitidepsin) is an antitumoral agent that induces apoptosis via Rac1-JNK activation. A proteomic approach using 2D-DIGE technology found 52 cytosolic and 39 membrane proteins differentially expressed in wild-type Aplidin-resistant HeLa cells, of which 27 were identified by MALDI-TOF mass spectrometry database interrogation. number involved pathways to be deregulated. Alterations Rab geranylgeranyltransferase, protein disulfide isomerase (PDI), cystathionine gamma-lyase, ezrin,...
Plitidepsin is an antitumor drug of marine origin currently in Phase III clinical trials multiple myeloma. In cultured cells, plitidepsin induces cell cycle arrest or acute apoptotic process which sustained activation c-Jun N-terminal kinase (JNK) plays a crucial role. With view to optimizing use plitidepsin, we have therefore evaluated the possibility using JNK as vivo biomarker response. this study, show that administration single dose mice xenografted with human cancer cells does indeed...
Abstract Objectives: Among patients being treated for cancer, cancer treatment-related fatigue (CTRF) remains a poorly understood condition with profound effect on quality of life. Our objective was to develop murine model CTRF, independent anemia, in order further understand its pathogenesis and provide conduit the development mechanistically-based therapeutic approaches. Methods: To determine optimal dose ionizing radiation produce fatigue, female BALB/c mice were irradiated 10 doses...
<h3>Background</h3> We describe KPMW101, which was created by chemical conjugation of a CD38-specific binder to clinical grade intravenous immunoglobulin (IvIg) pooled from healthy donors. Kleo's MATE<sup>TM</sup> technology enables efficient site-directed 'off-the-shelf' IvIg and allows the development antitumor agents with rapidly introduced target specificity. Our platform for engineering existing in cost-efficient manner. This relies on synthetic compounds that consists antibody...